We are live on ! Find out more
MACK

Merrimack Pharmaceuticals, Inc.
MACK

Delisted

MACK was delisted on the 17th of May, 2024.

Back to rankings

132 hedge funds and large institutions have $474M invested in Merrimack Pharmaceuticals, Inc. in 2014 Q3 according to their latest regulatory filings, with 28 funds opening new positions, 41 increasing their positions, 32 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

65% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 17

62% more call options, than puts

Call options by funds: $5.42M | Put options by funds: $3.35M

28% more repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 32

16% more capital invested

Capital invested by funds: $407M → $474M (+$66.7M)

9% more funds holding

Funds holding: 121 → 132 (+11)

Holders
132
Holders Change
+11
Holders Change %
+9.09%
% of All Funds
3.83%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
28
Increased
41
Reduced
32
Closed
17
Calls
$5.42M
Puts
$3.35M
Net Calls
+$2.07M
Net Calls Change
-$528K

Top Buyers

Rank Fund Capital Flow
1
CCM
Consonance Capital Management
New York
+$10.4M
2
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
+$4.19M
3
PCM
Portolan Capital Management
Massachusetts
+$2.87M
4
Jane Street
Jane Street
New York
+$2.19M
5
ACM
Alpha Capital Management
Texas
+$1.85M

Top Sellers

Rank Fund Capital Flow
1
Jennison Associates
Jennison Associates
New York
-$35.3M
2
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$5.58M
3
FCM
Farallon Capital Management
California
-$4.45M
4
Deutsche Bank
Deutsche Bank
Germany
-$3.71M
5
Goldman Sachs
Goldman Sachs
New York
-$2.37M
Name Holding Trade Value Shares
Change 		Change in
Stake
Renaissance Technologies
26
Renaissance Technologies
New York
$2.82M -$1.69M -31,546 -44%
Goldman Sachs
27
Goldman Sachs
New York
$2.72M -$2.37M -44,278 -53%
New York State Common Retirement Fund
28
New York State Common Retirement Fund
New York
$2.57M – – –
ACM
29
Alpha Capital Management
Texas
$2.4M +$1.85M +34,710 New
EI
30
EAM Investors
California
$2.4M +$1.05M +19,648 +131%
Charles Schwab
31
Charles Schwab
California
$2.39M +$34.1K +639 +2%
BIM
32
BlackRock Investment Management
Delaware
$2.39M +$2.46K +46 +0.1%
JMPWA
33
JP Morgan Private Wealth Advisors
California
$1.79M +$1.39M +25,992 New
BA
34
BlackRock Advisors
Delaware
$1.77M +$1.09M +20,365 +385%
Invesco
35
Invesco
Georgia
$1.77M -$1.3M -24,252 -49%
RFC
36
Russell Frank Company
Washington
$1.73M +$545K +10,206 +69%
CCM
37
Cadence Capital Management
Massachusetts
$1.69M +$1.31M +24,519 New
California State Teachers Retirement System (CalSTRS)
38
California State Teachers Retirement System (CalSTRS)
California
$1.59M +$13.1K +245 +1%
CT
39
Cambridge Trust
Massachusetts
$1.58M – – –
Marshall Wace
40
Marshall Wace
United Kingdom
$1.55M +$673K +12,591 +128%
D.E. Shaw & Co
41
D.E. Shaw & Co
New York
$1.49M +$1.15M +21,570 New
AllianceBernstein
42
AllianceBernstein
Tennessee
$1.41M – – –
Wellington Management Group
43
Wellington Management Group
Massachusetts
$1.41M +$925K +17,305 +570%
Citadel Advisors
44
Citadel Advisors
Florida
$1.4M +$1.01M +18,937 +1,446%
TA
45
Teachers Advisors
New York
$1.39M -$1.71K -32 -0.2%
U
46
UBS
Switzerland
$1.39M -$382K -7,140 -26%
Connor, Clark & Lunn Investment Management (CC&L)
47
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$1.38M +$1.07M +20,018 New
Two Sigma Investments
48
Two Sigma Investments
New York
$1.26M +$507K +9,479 +108%
PP
49
PDT Partners
New York
$1.12M +$606K +11,344 +234%
Ameriprise
50
Ameriprise
Minnesota
$1.09M +$841K +15,732 +393,300%
1
2
3 4 5

MACK Hedge Fund Activity: Q3 2014 in Review

132 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Merrimack Pharmaceuticals, Inc. (MACK) for Q3 2014, worth a combined $474M — up 16% from $407M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new MACK positions and 17 closed out — a net gain of 11 holders — while 41 added to existing stakes and 32 trimmed.

The largest buyer was Consonance Capital Management, opening a new position worth an estimated $10.4M. The largest seller was Jennison Associates, exiting entirely with an estimated $35.3M sold.

  • 132 institutional investors held Merrimack Pharmaceuticals, Inc. (MACK) as of Q3 2014, up from 121 in Q2 2014.
  • Funds reported $474M of Merrimack Pharmaceuticals, Inc. stock for Q3 2014, up 16% quarter-over-quarter.
  • 28 funds opened new Merrimack Pharmaceuticals, Inc. positions in Q3 2014 and 17 closed out, a net change of +11 holders.
  • The largest Merrimack Pharmaceuticals, Inc. buyer in Q3 2014 was Consonance Capital Management, an estimated $10.4M added.
  • The largest Merrimack Pharmaceuticals, Inc. seller in Q3 2014 was Jennison Associates, an estimated $35.3M sold.

Based on aggregated 13F filings for Q3 2014.